News | September 03, 2008

Study Finds Defibrillator Shocks May Increase Mortality, HRS Disputes Claim

September 3, 2008 – Research published this week in the New England Journal of Medicine said patients with heart failure in whom an ICD is implanted and receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks.

The article “Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure,” centered on a multi-center study about long-term prognosis after ICD therapy in patients because research in this area is limited.

“Like many other studies, the SCD-HeFT trial clearly demonstrates that ICD devices save lives,” said Dr. N.A. Mark Estes, president of the Heart Rhythm Society, which defends the use of ICDs. “While there is an association between patients who are shocked and an increased mortality, receiving a life-saving shock does not independently predict a patient’s survival rate.”

The HRS issued a release following publication of the article noting that while the study shows a link between ICD shocks and patient mortality, patients who received shocks were in worse health prior to the shock than those who were not shocked. The increased mortality rate is related to their overall health condition rather than ICD activity. Patients receive shocks to stop potentially life-threatening heart rhythms, and many recent studies have shown a drastic decrease in the number of inappropriate shocks. The HRS said.

The study followed 811 patients with heart failure who receive an implantable cardioverter–defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) and may have later receive therapeutic shocks from the ICD. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate, and all other ICD shocks were considered to be inappropriate for the purpose of the study.

The during the median follow-up period of 45.5 months, 269 patients (33.2 percent) received at least one ICD shock. Of those, 87 were considered inappropriate and 54 patients receiving both appropriate and inappropriate shocks.

In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes. Researchers also found an inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death. For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated. The most common cause of death among patients who received any ICD shock was progressive heart failure.

Researchers were from University of Washington; the Seattle Institute for Cardiac Research; Duke Clinical Research Institute; Durham, NC; University of Pennsylvania, Philadelphia; Portland Veterans Affairs Medical Center and Oregon Health Sciences University, Portland; Oregon Cardiology Associates, Eugene; University Hospital, London, ON, Canada; Johns Hopkins University, Baltimore; Institut de Cardiologie de Montréal, Université de Montréal, Montreal; Loyola University Medical Center, Maywood, IL; and the Mayo Clinic, Rochester, MN.

The Heart Rhythm Society reiterated its stance on the importance of ICDs in patients with life-threatening arrhythmias, and said ICDs are 99 percent effective in stopping life-threatening arrhythmias. The HRS said ICDs are the most successful therapy to treat ventricular fibrillation, the major cause of sudden cardiac arrest. However, only 35 percent of patients who could be helped by an ICD have one. ICDs continuously monitor the heart rhythm, automatically function as pacemakers for heart rates that are too slow, and deliver life-saving shocks if a dangerously fast heart rhythm is detected.

For more information: www.nejm.org, www.hrsonline.org

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init